

AMENDMENT TO
RULES COMMITTEE PRINT 118–10
OFFERED BY MR. CRENSHAW OF TEXAS

Beginning on page 368, line 1, strike section 744 and insert the following:

1 **SEC. 744. GRANT PROGRAM OF THE DEPARTMENT OF DE-**
2 **FENSE TO STUDY TREATMENT OF CERTAIN**
3 **CONDITIONS USING CERTAIN PSYCHEDELIC**
4 **SUBSTANCES.**

5 (a) **ESTABLISHMENT.**—Not later than 90 days after
6 the date of enactment of this Act, the Secretary of Defense
7 shall award grants to eligible entities to conduct research
8 on the treatment of members of the Armed Forces serving
9 on active duty with a covered condition using covered psy-
10 chedelic substances. Not later than 60 days after the date
11 of the enactment of this Act, the Secretary shall designate
12 a lead administrator to carry out the grant program under
13 this section.

14 (b) **ELIGIBLE ENTITIES.**—The Secretary may award
15 a grant under this section to any of the following:

16 (1) A department or agency of the Federal Gov-
17 ernment or a State government.

18 (2) An academic institution.

1 (3) A nonprofit entity.

2 (4) A public or private entity.

3 (c) USE OF GRANT FUNDS.—A recipient of a grant
4 awarded under this section may use the grant to—

5 (1) conduct one or more phase two clinical
6 trials for the treatment of covered conditions that—

7 (A) include members of the Armed Forces
8 serving on active duty as participants in the
9 clinical trial; and

10 (B) use individual or group therapy as-
11 sisted by covered psychedelic substances; or

12 (2) train practitioners to provide treatment to
13 members of the Armed Forces serving on active duty
14 for covered conditions using covered psychedelic sub-
15 stances.

16 (d) PARTICIPATION IN CLINICAL TRIALS.—The Sec-
17 retary shall authorize any member of the Armed Forces
18 serving on active duty who is diagnosed with a covered
19 condition to participate in a clinical trial that is conducted
20 using a grant awarded under this section or funds pro-
21 vided under subsection (e) and is authorized pursuant to
22 section 505 of the Federal Food, Drug, and Cosmetic Act
23 (21 U.S.C. 355), without regard to—

1 (1) whether the clinical trial involves a sub-
2 stance included in the schedule under section 202 of
3 the Controlled Substances Act (21 U.S.C. 812); or

4 (2) section 912a of title 10, United States Code
5 (article 112a of the Uniform Code of Military Jus-
6 tice).

7 (e) ADDITIONAL AUTHORITY.—Subject to the avail-
8 ability of appropriations, in addition to awarding grants
9 under this section, the Secretary shall provide funds for
10 a clinical research trial using covered psychedelic sub-
11 stances that is authorized pursuant to section 505 of the
12 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355)
13 and includes members of the Armed Forces serving on ac-
14 tive duty as participants in the trial.

15 (f) REPORT REQUIRED.—Not later than 180 days
16 after the date of the enactment of this Act, and every 180
17 days thereafter, the Secretary shall submit to the Commit-
18 tees on Armed Services of the House of Representatives
19 and the Senate a report on grants awarded under this sec-
20 tion, including the following:

21 (1) Identification of clinics designated to host
22 activities under such a grant.

23 (2) A description of entities to whom the Sec-
24 retary has awarded such a grant.

1 (3) The number of members of the Armed
2 Forces serving on active duty who participated in a
3 clinical trial described in subsection (d).

4 (4) Information on the findings of such clinical
5 trials.

6 (g) AUTHORIZATION OF APPROPRIATIONS.—

7 (1) INCREASE.—Notwithstanding the amounts
8 set forth in the funding tables in division D, the
9 amount authorized to be appropriated in section
10 1405 for the Defense Health Program, as specified
11 in the corresponding funding table in section 4501
12 for “Defense Health Program, R&D research” is
13 hereby increased by \$15,000,000 (with the amount
14 of such increase to be used in support of the grant
15 program under this section).

16 (2) OFFSET.—Notwithstanding the amounts set
17 forth in the funding tables in division D, the amount
18 authorized to be appropriated in section 301, as
19 specified in the corresponding funding table in sec-
20 tion 4301, for “administration and service-wide ac-
21 tivities, Office of the Secretary of Defense”, line
22 490, is hereby reduced by \$15,000,000.

23 (h) DEFINITIONS.—In this section:

24 (1) The term “covered condition” means any of
25 the following:

1 (A) Post-traumatic stress.

2 (B) Traumatic brain injury.

3 (2) The term “covered psychedelic substances”

4 means any of the following:

5 (A) 3,4-Methylenedioxy-methamphetamine

6 (commonly known as “MDMA”).

7 (B) Psilocybin.

8 (C) Ibogaine.

9 (D) 5-Methoxy-N,N-dimethyltryptamine

10 (commonly known as “5-MeO-DMT”).

11 (3) The term “Secretary” means the Secretary

12 of Defense.

13 (4) The term “State” has the meaning given

14 such term in section 901 of title 32, United States

15 Code.

